Zeyzelf^®
rivastigmine twice weekly transdermal patch

UK-ZEY-99 April 2026

Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk. Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk

UK-ZEY-98 April 2026

This page is intended for an audience in the UK

Are you a:

UK HEALTH CARE PROFESSIONAL PATIENT OR CARER MEMBER OF THE PUBLIC

UK-ZEY-98a April 2026

You are leaving the site

You are now leaving the Luye Zeyzelf product website to go to
an external website over which Luye Pharma has no control
and to which our Privacy Policy does not apply. You are
solely responsible for your interactions with that website.
Click OK to proceed.

You are now leaving the Luye Zeyzelf product website
and will be redirected to our corporate site which
will open in a new window

Click OK to proceed.

You'll be redirected to:

UK-ZEY-105 April 2026

To receive the resource please provide your name, email address and NHS postal address below:

"*" indicates required fields

X/Twitter

This field is for validation purposes and should be left unchanged.

Name*

Email*

NHS Postal address*

NHS Postcode*

Consent*

I agree to be sent cost saving information from Luye Pharma now and in the future*

Consent

I agree to be sent product updates and promotional material and from Luye Pharma now and in the future

UK-ZEY-100ab April 2026

To view the resource please provide your name and email address: